Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Am Coll Radiol. 2009 Jan;6(1):33-7. doi: 10.1016/j.jacr.2008.07.011.

Randomized prospective trials of innovative radiotherapy technology are necessary.

Author information

  • University of Louisville, Louisville, Kentucky 40202-3866, USA. edward.halperin@louisville.edu

Abstract

The most important clinical problem facing radiation oncology is whether randomized prospective trials are necessary to assess innovative technologies. Some radiation oncologists feel strongly that randomized trials are unnecessary, because highly conformal beams are self-evidently worthy, and the only interesting question is the magnitude of the gain, not whether a gain is achievable. Supporters of randomized trials invoke a long list of historical examples wherein such trials demonstrated the uselessness of technologies that were thought to be "self-evidently" better. Physicians with financial or academic career interest in the promotion of innovative technologies are not objective parties in this debate. There are also considerable opportunity costs of investments in expensive innovative technologies. It is possible to identify innovations that should be required to meet the standard of proof of a benefit in a randomized prospective clinical trial before being introduced into widespread clinical practice.

PMID:
19111269
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk